Preparation method of drug-loaded layer-by-layer self-assembly coating

Abstract

The invention discloses a preparation method of a drug-loaded layer-by-layer self-assembly coating. The preparation method comprises the following steps: A, performing aminating modification on hyaluronic acid by using dopamine; B, performing aminating modification on chitosan by using 3,4-dihydroxyl phenylpropionic acid; C, dissolving the dopamine in a trimethylol aminomethane solution with a PH value of 8.5 to form a mixed solution with dopamine concentration of 2mg/mL; soaking a matrix material in the mixed solution, reacting for time of t1 at a constant temperature, and washing the matrix material; D, preparing a modified hyaluronic acid solution with concentration of 2mg/mL and a PH value of 5.5, and dissolving a loaded drug into the modified hyaluronic acid solution to obtain a solution S1; preparing a modified chitosan solution with concentration of 2mg/mL, and dissolving the loaded drug to obtain a solution S2; soaking the matrix material obtained in step C into the solution S2 for a time of t2; then soaking in the solution S1 for a time of t3; and E, repeating the step D. The drug-loaded layer-by-layer self-assembly coating has good PH response and stability and is suitable for the matrix materials of any shapes; and moreover, the preparation method has the advantages of simple operation, simpleness of needed equipment, low preparation cost and high applicability.

Description

technical field [0001] The invention relates to the field of biomedical materials, in particular to a method for preparing a drug-loaded layer-by-layer self-assembled coating. Background technique [0002] In recent years, cardiovascular diseases have become a major factor that threatens human health, and the number of deaths worldwide ranks first in human disease deaths every year; clinically, percutaneous coronary intervention has become the main treatment for cardiovascular diseases. In the past 30 years, interventional therapy has also undergone development, from early pure balloon dilatation and bare metal stents to the current drug-eluting vascular stent, and the future degradable vascular stent; in order to avoid clinical application A series of complications associated with bare metal stents and drug-eluting stents, including thrombosis, stent restenosis, inflammatory reactions, etc.; usually various modifications are made on the surface of the stent and drugs are lo...

AI Technical Summary

Problems solved by technology

[0002] In recent years, cardiovascular diseases have become a major factor that threatens human health, and the number of deaths worldwide ranks first in human disease deaths every year; clinically, percutaneous coronary intervention has become the main treatment for cardiovascular diseases. In the past 30 years, interventional therapy has also undergone development, from early pure balloon dilatation and bare metal stents to the current drug-eluting vascular stent, and the future degradable vascular stent; in order to avoid clinical application A series of complications associated with bare metal stents and drug-eluting stents, including thrombosis, stent restenosis, inflammatory reactions, etc.; usually various modifications are made on the surface of the stent and drugs are loaded to achieve better therapeutic effects ; At present, it is a commonly used modification method t